Table 4. Multiple stepwise regression analysis showing variables independently associated with C-IMT (mm) in men and women.
Men |
Women |
||||||||
---|---|---|---|---|---|---|---|---|---|
Independent variables | β | SEM | Standardized β | P | Independent variables | β | SEM | Standardized β | P |
Model 1 | |||||||||
Age | 0.003 | 0.001 | 0.325 | <0.001 | Age | 0.002 | 0.001 | 0.312 | <0.001 |
Smoking status | 0.019 | 0.004 | 0.164 | <0.001 | HOMA-IR | 0.001 | 0.001 | 0.102 | 0.017 |
W | 0.001 | 0.001 | 0.163 | <0.001 | SBP | 0.001 | 0.001 | 0.104 | 0.023 |
LDL-c | 0.011 | 0.002 | 0.203 | <0.001 | Anti-hypertensive therapy | 0.011 | 0.005 | 0.107 | 0.018 |
SBP | 0.001 | 0.001 | 0.102 | 0.010 | |||||
2hPG | 0.001 | 0.001 | 0.106 | 0.007 | |||||
Model 2 | |||||||||
Age | 0.003 | 0.001 | 0.325 | <0.001 | Age | 0.002 | 0.001 | 0.311 | <0.001 |
Smoking status | 0.019 | 0.004 | 0.164 | <0.001 | HOMA-IR | 0.001 | 0.001 | 0.108 | 0.011 |
W | 0.001 | 0.001 | 0.161 | <0.001 | SBP | 0.001 | 0.001 | 0.104 | 0.022 |
LDL-c | 0.011 | 0.002 | 0.207 | <0.001 | Anti-hypertensive therapy | 0.011 | 0.005 | 0.104 | 0.020 |
SBP | 0.001 | 0.001 | 0.102 | 0.010 | |||||
2hPG | 0.001 | 0.001 | 0.108 | 0.006 | |||||
Model 3 | |||||||||
Age | 0.003 | 0.001 | 0.324 | <0.001 | Age | 0.002 | 0.001 | 0.312 | <0.001 |
Smoking status | 0.019 | 0.004 | 0.165 | <0.001 | HOMA-IR | 0.001 | 0.001 | 0.102 | 0.017 |
VFA | 0.001 | 0.001 | 0.107 | 0.007 | SBP | 0.001 | 0.001 | 0.104 | 0.023 |
LDL-c | 0.011 | 0.002 | 0.205 | <0.001 | Anti-hypertensive therapy | 0.011 | 0.005 | 0.107 | 0.018 |
SBP | 0.001 | 0.001 | 0.107 | 0.009 | |||||
2hPG | 0.001 | 0.001 | 0.116 | 0.003 |
Abbreviations: 2hPG, 2-h post-OGTT plasma glucose; BMI, body mass index; CRP, C reactive protein; DBP, diastolic blood pressure; HDL-c, high-density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment-insulin resistance; LDL-c, low-density lipoprotein cholesterol; SBP, systolic blood pressure; SFA, subcutaneous fat area; VFA, visceral fat area; W, waist circumference.
Variables included in the original models are obesity indices (Model 1: BMI, W, % fat, VFA and SFA; Model 2: BMI and W; Model 3: % fat, VFA and SFA) and basic CVD risk factors, including age, smoking status, SBP, DBP, HOMA-IR, 2hPG, LDL-c, HDL-c, CRP, anti-hypertensive therapy, anti-diabetic therapy and lipid-lowering therapy. For women we also adjusted the menopausal status.